<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32641</article-id><article-id pub-id-type="doi">10.17116/terarkh2016881025-34</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Evaluation of markers for renal graft dysfunction in patients with type 1 diabetes mellitus after kidney transplantation and simultaneous pancreas-kidney transplantation</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка маркеров дисфункции почечного трансплантата у пациентов с сахарным диабетом 1-го типа после трансплантации почки и сочетанной трансплантации почки и поджелудочной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Glazunova</surname><given-names>A M</given-names></name><name xml:lang="ru"><surname>Глазунова</surname><given-names>А М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Arutyunova</surname><given-names>M S</given-names></name><name xml:lang="ru"><surname>Арутюнова</surname><given-names>М С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tarasov</surname><given-names>E V</given-names></name><name xml:lang="ru"><surname>Тарасов</surname><given-names>Е В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nikankina</surname><given-names>L V</given-names></name><name xml:lang="ru"><surname>Никанкина</surname><given-names>Л В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ilyin</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Ильин</surname><given-names>А В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shamkhalova</surname><given-names>M Sh</given-names></name><name xml:lang="ru"><surname>Шамхалова</surname><given-names>М Ш</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shestakova</surname><given-names>M V</given-names></name><name xml:lang="ru"><surname>Шестакова</surname><given-names>М В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Moysyuk</surname><given-names>Ya G</given-names></name><name xml:lang="ru"><surname>Мойсюк</surname><given-names>Я Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Эндокринологический научный центр Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Федеральный научный центр трансплантологии и искусственных органов им. акад. В.И. Шумакова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2016</year></pub-date><volume>88</volume><issue>10</issue><issue-title xml:lang="en">VOL 88, NO10 (2016)</issue-title><issue-title xml:lang="ru">ТОМ 88, №10 (2016)</issue-title><fpage>25</fpage><lpage>34</lpage><history><date date-type="received" iso-8601-date="2020-04-11"><day>11</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32641">https://ter-arkhiv.ru/0040-3660/article/view/32641</self-uri><abstract xml:lang="en"><p>Aim. To study the markers of renal graft dysfunction in patients with type 1 diabetes mellitus (T1DM) after kidney transplantation (KT) and simultaneous pancreas-kidney transplantation (SPKT). Subjects and methods. The investigation enrolled 20 patients after successful SPKT and 41 patients after KT (of them 21 received continuous subcutaneous insulin infusion with an insulin doser; 20 had multiple insulin injections). The periods after KT and SPKT at patient inclusion were 8 (7; 8) and 11 (8; 18) months, respectively. A control group comprised 15 patients with T1DM without diabetic nephropathy. The patients were matched for gender, age, and T1DM duration. At a 9-month follow-up, the main biomarkers of kidney graft dysfunction were identified using the standard kits: Cystatin C (Cys C; serum; urine), NGAL, KIM-1, Podocin, Nephrin, IL-18, MMP-9 (urine), TGF-β1, VEGF-A, and Osteopontin (OPN; serum). Fasting blood was taken; a morning urinary portion was examined. Results. The posttransplantation glomerular filtration rate (GFR) in the patients corresponded to Stage C2; albuminuria did to Category A1 chronic kidney disease. Despite successful SPKT in the group of patients with T1DM, as in that of patients after isolated KT, there was a statistically significant increase in the level of kidney dysfunction markers (Cys C, NGAL, Podocin, and OPN) versus the control group regardless of the compensation for glucose metabolism. compensation. It was found that the level of Cys C was high and correlated negatively with GFR (r=–0.36; p&lt;0.05) and positively with the level of albuminuria (r=0.40; p&lt;0.05). There was also a direct correlation of urinary podocin concentrations with blood creatinine levels (r=0.35; p&lt;0.05) and that of NGAL with albuminuria (r=0.35; p&lt;0.05) in recipients after transplantation. Conclusion. The high levels of biomarkers for kidney graft dysfunction in the examinees (including subjects after SPKT) reflect the persistence of graft microstructural injuries in clinically stable function.</p></abstract><trans-abstract xml:lang="ru"><p>Резюме Цель исследования. Изучить маркеры дисфункции почечного трансплантата у больных сахарным диабетом 1-го типа (СД-1) после трансплантации почки (ТП) и сочетанной ТП и поджелудочной железы (СТПЖиП). Материалы и методы. В исследование включили 20 пациентов после успешной СТПЖиП и 41 пациента после ТП (из них 21 получали постоянную подкожную инфузию инсулина с помощью инсулинового дозатора, 20 — многократные инъекции инсулина). Пострансплантационный период на момент включения пациентов с ТП составлял 8 (7; 8) мес, группы с СТПЖиП — 11 (8; 18) мес. Контрольную группу составили 15 пациентов с СД-1 без диабетической нефропатии. Пациенты сопоставимы по полу, возрасту и длительности СД-1. Через 9 мес наблюдения определены основные биомаркеры дисфункции нефротрансплантата с помощью стандартных наборов: Цистатин C (Cys C; сыворотка, моча); NGAL, KIM-1, Подоцин, Нефрин, IL-18, ММР-9 (моча), TGF-β1, VEGF-А, Остеопонтин (OPN; сыворотка крови). Забор крови осуществляли натощак, исследовали утреннюю порцию мочи. Результаты. Скорость клубочковой фильтрации (СКФ) у пациентов после трансплантации соответствовала стадии С2, альбуминурия категории А1 хронической болезни почек. Несмотря на успешную СТПЖиП в группе пациентов с СД-1, как и в группе пациентов после изолированной ТП, выявлено статистически значимое повышение уровня маркеров дисфункции почек (Cys C, NGAL, Подоцин, OPN) по сравнению с контрольной группой независимо от компенсации углеводного обмена. Определен высокий уровень и отрицательная связь уровня Cys C крови с СКФ (r=–0,36; р&lt;0,05) и положительная с уровнем альбуминурией (r=0,40; р&lt;0,05), а также прямая связь концентрации подоцина в моче с уровнем креатинина в крови (r=0,35; p&lt;0,05) и NGAL с альбуминурией (r=0,35; p&lt;0,05) у реципиентов после трансплантации. Заключение. Высокие уровни биомаркеров дисфункции почечного трансплантата у обследованных пациентов (включая лиц после СТПЖиП) отражают персистирование повреждения микроструктур трансплантатов при клинически стабильной функции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>diabetic nephropathy</kwd><kwd>pancreas-kidney transplantation</kwd><kwd>kidney transplantation</kwd><kwd>biomarkers for kidney graft dysfunction</kwd><kwd>complications of diabetes mellitus</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>диабетическая нефропатия</kwd><kwd>трансплантация поджелудочной железы и почки</kwd><kwd>трансплантация почки</kwd><kwd>биомаркеры дисфункции почечного трансплантата</kwd><kwd>осложнения сахарного диабета</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kim SC, Page EK, Knechtle SJ. Urine proteomics in kidney transplantation. Transplantat Rev. 2014;28(1):15-20. doi:10.1016/j.trre.2013.10.004</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>First MR. Renal function as a predictor of long-term graft survival in renal transplant patients. Nephrol Dial Transplant. 2003;18(suppl 1):i3-i6. doi:10.1093/ndt/gfg1027</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Rosner MH. Biomarker in renal disease. Chapter 6. Biomarker in kidney transplantation. Nova science Publisher inc; 2008.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hariharan S, McBride MA, Cohen EP. Evolution of Endpoints for Renal Transplant Outcome. Am J Transplant. 2003;3(8):933-941. doi:10.1034/j.1600-6143.2003.00176.x</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ge F, Dai Q, Gong W. Biomarkers for renal transplantation: where are we? Int J Nephrol Renovasc Dis. 2013;6:187-191. doi:10.2147/IJNRD.S39806</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gong W, Whitcher GH, Townamchai N, et al. Biomarkers for Monitoring Therapeutic Side Effects or Various Supratherapeutic Confounders after Kidney Transplantation. Transplant Proceed. 2012;44(5):1265-1269. doi:10.1016/j.transproceed.2011.11.069</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Stevens LA, Schmid CH, Greene T et al. Factors Other than GFR Affecting Serum Cystatin C Levels. Kidney Int. 2009;75(6):652-660. doi:10.1038/ki.2008.638</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Данович Г.М. Трансплантация почки. Глава 9. Первые три месяца после трансплантации почки. М.: ГЭОТАР-Медиа; 2013.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dupont PJ, Psimenou E, Lord R et al. Late Recurrent Urinary Tract Infections May Produce Renal Allograft Scarring Even in the Absence of Symptoms or Vesicoureteric Reflux. Transplantation. 2007;84(3):351-355. doi:10.1097/01.tp.0000275377.09660.fa</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Locke JE, Zachary AA, Warren DS et al. Proinflammatory Events Are Associated with Significant Increases in Breadth and Strength of HLA-Specific Antibody. Am J Transplant. 2009;9(9):2136-2139. doi:10.1111/j.1600-6143.2009.02764.x</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Thrailkill KM, Moreau CS, Cockrell GE et al. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine. 2010;37(2):336-343. doi:10.1007/s12020-010-9308-6</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Mårtensson J, Bell M, Oldner A, et al. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010;36(8):1333-1340. doi:10.1007/s00134-010-1887-4</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>van Timmeren MM, Vaidya VS, van Ree RM et al. High Urinary Excretion of Kidney Injury Molecule-1 Is an Independent Predictor of Graft Loss in Renal Transplant Recipients. Transplantation. 2007;84(12):1625-1630. doi:10.1097/01.tp.0000295982.78039.ef</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Данович Г.М. Трансплантация почки. Глава 1. Возможности лечения пациентов в терминальной стадии хронической почечной недостаточности. М.: ГЭОТАР-Медиа; 2013.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pippin J, Kumar V, Stein A et al. The Contribution of Podocytes to Chronic Allograft Nephropathy. Nephron Exper Nephrol. 2009;111(1):e1-e10. doi:10.1159/000178762</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Forbes JM, Cooper ME. Mechanisms of Diabetic Complications. Physiol Revi. 2013;93(1):137-188. doi:10.1152/physrev.00045.2011</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Opdenakker G, Van den Steen PE, Dubois B et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukocyte Biol. 2001;69(6):851-859.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Hartmann A, Sagedal S, Hjelmesæth J. The Natural Course of Cytomegalovirus Infection and Disease in Renal Transplant Recipients. Transplantation. 2006;82:S15-S17. doi:10.1097/01.tp.0000230460.42558.b0</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zhang Z-X, Shek K, Wang S, et al. Osteopontin Expressed in Tubular Epithelial Cells Regulates NK Cell-Mediated Kidney Ischemia Reperfusion Injury. J Immunol. 2010;185(2):967-973. doi:10.4049/jimmunol.0903245</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lorenzen JM, Hafer C, Faulhaber-Walter R, et al. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol DialTransplant. 2010. doi:10.1093/ndt/gfq498</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Gordin D, Forsblom C, Panduru NM et al. Osteopontin Is a Strong Predictor of Incipient Diabetic Nephropathy, Cardiovascular Disease, and All-Cause Mortality in Patients With Type 1 Diabetes. Diabetes Care. 2014;37(9):2593-2600. doi:10.2337/dc14-0065</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Jin Z-K, Tian P-X, Wang X-Z et al. Kidney injury molecule-1 and osteopontin: New markers for prediction of early kidney transplant rejection. Mol Immunol.2013;54(3-4):457-464. doi:10.1016/j.molimm.2013.01.013</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Lorenzen JM, Martino F, Scheffner I et al. Fetuin, Matrix-Gla Protein and Osteopontin in Calcification of Renal Allografts. PLoS ONE. 2012;7(12):e52039. doi:10.1371/journal.pone.0052039</mixed-citation></ref></ref-list></back></article>
